To explore these 12 signatures, we correlated their activities (i.e., the estimated number of mutations contributed by each signature to the total mutational burden of the tumor) to the MSI status and POLE/POLD1 exonuclease domain mutation status of each tumor in the cohort. The gene discussed is POLD1; the disease is neoplasm.